AGIOS PHARMACEUTICALS, INC. (AGIO) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 98.34M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 7.87M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $98.34M | $7.87M | (m) |
| 2026-03-31 | (m) | $66.05M | $6.58M | (m) |
| 2025-12-31 | (m) | $54.03M | $6.34M | (m) |
| 2025-09-30 | (m) | $44.79M | $5.73M | (m) |
| 2025-06-30 | (m) | $40.88M | $4.83M | (m) |
| 2025-03-31 | (m) | $37.03M | $4.62M | (m) |
| 2024-12-31 | (m) | $36.50M | $4.17M | (m) |
| 2024-09-30 | (m) | $32.87M | $3.49M | (m) |
| 2024-06-30 | (m) | $31.31M | $3.34M | (m) |
| 2024-03-31 | (m) | $29.40M | $2.95M | (m) |
| 2023-12-31 | (m) | $26.82M | $2.88M | (m) |
| 2023-09-30 | (m) | $24.03M | $2.71M | (m) |
| 2023-06-30 | (m) | $20.15M | $2.59M | (m) |
| 2023-03-31 | (m) | $19.02M | $1.92M | (m) |
| 2022-12-31 | (m) | $14.24M | $1.70M | (m) |
| 2022-09-30 | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $0.00 | $0.00 | (m) |
| 2021-09-30 | (m) | $44.05M | $959.00K | (m) |
| 2021-06-30 | (m) | $78.75M | $1.60M | (m) |
| 2021-03-31 | (m) | $116.10M | $2.27M | (m) |
| 2020-12-31 | (m) | $203.20M | $2.81M | (m) |
| 2020-09-30 | (m) | $194.59M | $2.13M | (m) |
| 2020-06-30 | (m) | $185.91M | $1.89M | (m) |
| 2020-03-31 | (m) | $174.78M | $1.52M | (m) |
| 2019-12-31 | (m) | $117.91M | $1.32M | (m) |
| 2019-09-30 | (m) | $112.48M | $1.73M | (m) |
| 2019-06-30 | (m) | $101.66M | $2.03M | (m) |
| 2019-03-31 | (m) | $115.85M | $1.73M | (m) |
| 2018-12-31 | (m) | $94.39M | $1.40M | (m) |
| 2018-09-30 | (m) | $74.17M | (m) | (m) |
| 2018-06-30 | (m) | $70.33M | (m) | (m) |
| 2018-03-31 | (m) | $41.27M | (m) | (m) |
| 2017-12-31 | (m) | $43.01M | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $49.12M | (m) | (m) |
| 2016-12-31 | (m) | $69.89M | (m) | (m) |
| 2016-09-30 | (m) | $53.46M | (m) | (m) |
| 2016-06-30 | (m) | $49.96M | (m) | (m) |
| 2016-03-31 | (m) | $56.20M | (m) | (m) |
| 2015-12-31 | (m) | $59.12M | (m) | (m) |
| 2015-09-30 | (m) | $67.54M | (m) | (m) |
| 2015-06-30 | (m) | $95.96M | (m) | (m) |
| 2015-03-31 | (m) | $91.15M | (m) | (m) |
| 2014-12-31 | (m) | $65.36M | (m) | (m) |
| 2014-09-30 | (m) | $57.47M | (m) | (m) |
| 2014-06-30 | (m) | $29.85M | (m) | (m) |
| 2014-03-31 | (m) | $27.65M | (m) | (m) |
| 2013-12-31 | (m) | $25.55M | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $25.11M | (m) | (m) |
| 2012-12-31 | (m) | $25.11M | (m) | (m) |
| 2012-09-30 | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $21.84M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |